125 related articles for article (PubMed ID: 37151105)
21. Correlations between biochemical markers of bone turnover and bone density responses in patients with glucocorticoid-induced osteoporosis treated with teriparatide or alendronate.
Burshell AL; Möricke R; Correa-Rotter R; Chen P; Warner MR; Dalsky GP; Taylor KA; Krege JH
Bone; 2010 Apr; 46(4):935-9. PubMed ID: 20060081
[TBL] [Abstract][Full Text] [Related]
22. Alendronate in primary hyperparathyroidism: a double-blind, randomized, placebo-controlled trial.
Khan AA; Bilezikian JP; Kung AW; Ahmed MM; Dubois SJ; Ho AY; Schussheim D; Rubin MR; Shaikh AM; Silverberg SJ; Standish TI; Syed Z; Syed ZA
J Clin Endocrinol Metab; 2004 Jul; 89(7):3319-25. PubMed ID: 15240609
[TBL] [Abstract][Full Text] [Related]
23. The impact of mild Leydig cell dysfunction following cytotoxic chemotherapy on bone mineral density (BMD) and body composition.
Howell SJ; Radford JA; Adams JE; Shalet SM
Clin Endocrinol (Oxf); 2000 May; 52(5):609-16. PubMed ID: 10792341
[TBL] [Abstract][Full Text] [Related]
24. Assessment of Osteogenic Exercise Efficacy via Bone Turnover Markers in Premenopausal Women: A Randomized Controlled Trial.
Sanchez-Trigo H; Kemmler W; Duque G; Sañudo B
Int J Sport Nutr Exerc Metab; 2024 Jan; 34(1):20-29. PubMed ID: 37917954
[TBL] [Abstract][Full Text] [Related]
25. Randomized trial of once-weekly parathyroid hormone (1-84) on bone mineral density and remodeling.
Black DM; Bouxsein ML; Palermo L; McGowan JA; Newitt DC; Rosen E; Majumdar S; Rosen CJ;
J Clin Endocrinol Metab; 2008 Jun; 93(6):2166-72. PubMed ID: 18349061
[TBL] [Abstract][Full Text] [Related]
26. Effects of intravenous zoledronic acid plus subcutaneous teriparatide [rhPTH(1-34)] in postmenopausal osteoporosis.
Cosman F; Eriksen EF; Recknor C; Miller PD; Guañabens N; Kasperk C; Papanastasiou P; Readie A; Rao H; Gasser JA; Bucci-Rechtweg C; Boonen S
J Bone Miner Res; 2011 Mar; 26(3):503-11. PubMed ID: 20814967
[TBL] [Abstract][Full Text] [Related]
27. Testicular cancer survivors have shorter anogenital distance that is not increased by 1 year of testosterone replacement therapy.
Priskorn L; Kreiberg M; Bandak M; Lauritsen J; Daugaard G; Petersen JH; Aksglaede L; Juul A; Jørgensen N
Hum Reprod; 2021 Aug; 36(9):2443-2451. PubMed ID: 34223605
[TBL] [Abstract][Full Text] [Related]
28. PINP as an aid for monitoring patients treated with teriparatide.
Tsujimoto M; Chen P; Miyauchi A; Sowa H; Krege JH
Bone; 2011 Apr; 48(4):798-803. PubMed ID: 21168536
[TBL] [Abstract][Full Text] [Related]
29. Effects of denosumab treatment and discontinuation on bone mineral density and bone turnover markers in postmenopausal women with low bone mass.
Bone HG; Bolognese MA; Yuen CK; Kendler DL; Miller PD; Yang YC; Grazette L; San Martin J; Gallagher JC
J Clin Endocrinol Metab; 2011 Apr; 96(4):972-80. PubMed ID: 21289258
[TBL] [Abstract][Full Text] [Related]
30. Five years of anti-resorptive activity after a single dose of zoledronate--results from a randomized double-blind placebo-controlled trial.
Grey A; Bolland MJ; Horne A; Wattie D; House M; Gamble G; Reid IR
Bone; 2012 Jun; 50(6):1389-93. PubMed ID: 22465268
[TBL] [Abstract][Full Text] [Related]
31. Declining serum bone turnover markers are associated with the short-term positive change of lumbar spine bone mineral density in postmenopausal women.
Zhao S; Mo X; Wen Z; Liu M; Chen Z; Lin W; Huang Z; Chen B
Menopause; 2022 Jan; 29(3):335-343. PubMed ID: 35102102
[TBL] [Abstract][Full Text] [Related]
32. Early changes in bone turnover and bone mineral density after discontinuation of long-term oral bisphosphonates: a post hoc analysis.
Saag K; Cosman F; De Villiers T; Langdahl B; Scott BB; Denker AE; Pong A; Santora AC
Osteoporos Int; 2021 Sep; 32(9):1879-1888. PubMed ID: 33606045
[TBL] [Abstract][Full Text] [Related]
33. A randomized trial of nasal spray salmon calcitonin in men with idiopathic osteoporosis: effects on bone mineral density and bone markers.
Trovas GP; Lyritis GP; Galanos A; Raptou P; Constantelou E
J Bone Miner Res; 2002 Mar; 17(3):521-7. PubMed ID: 11874243
[TBL] [Abstract][Full Text] [Related]
34. Additional beneficial effects of alendronate in growth hormone (GH)-deficient adults with osteoporosis receiving long-term recombinant human GH replacement therapy: a randomized controlled trial.
Biermasz NR; Hamdy NA; Janssen YJ; Roelfsema F
J Clin Endocrinol Metab; 2001 Jul; 86(7):3079-85. PubMed ID: 11443170
[TBL] [Abstract][Full Text] [Related]
35. Duration of antiresorptive effects of low-dose zoledronate in osteopenic postmenopausal women: a randomized, placebo-controlled trial.
Grey A; Bolland M; Mihov B; Wong S; Horne A; Gamble G; Reid IR
J Bone Miner Res; 2014 Jan; 29(1):166-72. PubMed ID: 23761303
[TBL] [Abstract][Full Text] [Related]
36. Effects of 42 months of GH treatment on bone mineral density and bone turnover in GH-deficient adults.
Välimäki MJ; Salmela PI; Salmi J; Viikari J; Kataja M; Turunen H; Soppi E
Eur J Endocrinol; 1999 Jun; 140(6):545-54. PubMed ID: 10377504
[TBL] [Abstract][Full Text] [Related]
37. Dexlansoprazole and Esomeprazole Do Not Affect Bone Homeostasis in Healthy Postmenopausal Women.
Hansen KE; Nieves JW; Nudurupati S; Metz DC; Perez MC
Gastroenterology; 2019 Mar; 156(4):926-934.e6. PubMed ID: 30445008
[TBL] [Abstract][Full Text] [Related]
38. Alendronate for osteoporosis in men with androgen-repleted hypogonadism.
Shimon I; Eshed V; Doolman R; Sela BA; Karasik A; Vered I
Osteoporos Int; 2005 Dec; 16(12):1591-6. PubMed ID: 16362147
[TBL] [Abstract][Full Text] [Related]
39. Efficacy of Yigu® versus Aclasta® in Chinese postmenopausal women with osteoporosis: a multicenter prospective study.
Li M; Cheng Q; Huo YN; Chao AJ; He L; Xue QY; Xu J; Yan SG; Jin H; Zhang ZL; Lin JH; Jin XL; Xu YJ; Liu F; Xia WB
Arch Osteoporos; 2022 Jan; 17(1):14. PubMed ID: 35020038
[TBL] [Abstract][Full Text] [Related]
40. Bone turnover and bone mineral density in HIV-1 infected Chinese taking highly active antiretroviral therapy -a prospective observational study.
Zhang L; Su Y; Hsieh E; Xia W; Xie J; Han Y; Cao Y; Li Y; Song X; Zhu T; Li T; Yu W
BMC Musculoskelet Disord; 2013 Jul; 14():224. PubMed ID: 23899016
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
